On April 27, 2020, Sean Tong, a member of the Board of Directors of Viela Bio, Inc. notified the Company in writing that he would not stand for re-election to the Board upon the expiration of his current term as a Class I director at the 2020 annual meeting of the Company's stockholders. On April 24, 2020, the Board elected Rachelle Jacques to the Board as a Class I director, effective May 1, 2020, for a term to continue until the 2020 annual meeting of the Company's stockholders and thereafter until Ms. Jacques' successor has been elected and qualified or until her earlier death, resignation or removal. Rachelle Jacques serves as the Chief Executive Officer of Enzyvant Therapeutics, Inc., focused on developing therapies for patients with rare diseases, since February 2019.